Last updated: July 17, 2026
Executive summary
Purdue Pharma L.P. v. Accord Healthcare, Inc., No. 23-1953, is a federal appellate dispute tied to Purdue’s efforts to block Accord Healthcare from marketing a Purdue-associated opioid product covered by Purdue’s IP and FDA Orange Book listings. The case tracks the post-judgment posture of the district court litigation and centers on the scope and enforceability of Purdue’s asserted patents or patent-listed rights under the Hatch-Waxman framework, with the appeal framed around infringement, validity, and/or procedural entitlement to relief. A complete litigation summary with specific holdings, claims-in-suit, patent numbers, and the appeal outcome cannot be produced from the provided input alone.
What is Purdue Pharma L.P. v. Accord Healthcare, Inc. 23-1953 about?
Answer: The matter is an appeal in the Purdue v. Accord Healthcare litigation, brought under the appellate docket No. 23-1953, with Purdue acting as the appellant or appellee contesting an adverse or challenged decision from the U.S. district court. It concerns whether Accord could lawfully enter or continue with a product whose marketing is regulated by FDA and whose approval is tied to Orange Book patent listings.
Which product and active ingredient are implicated?
Answer: Not specified in the input.
What type of IP dispute is this?
Answer: The case is consistent with Hatch-Waxman-type patent enforcement (infringement/validity and entry-forcing injunctive relief tied to Orange Book patents) but the specific statutory posture (e.g., 21 U.S.C. § 355(j) Paragraph IV, § 505(b)(2), or other) is not specified in the input.
What patents protect Purdue’s product against Accord in 23-1953?
Answer: The asserted patent estate (patent numbers, claim groups, and whether the patents are composition, method-of-use, formulation, or manufacturing patents) is not provided in the input.
What is the patent asserted and what claims were at issue?
Answer: Not provided.
How many patents are involved and which jurisdictions apply?
Answer: Not provided. A precise count of patents and their jurisdictional reach is not available from the provided text.
What did the district court decide before the appeal in 23-1953?
Answer: The district court disposition, including whether the court granted or denied preliminary/injunction relief and the basis (infringement, invalidity, non-infringement, or procedural grounds), is not provided in the input.
What were the key legal issues on appeal?
Answer: Not provided. Typical issues in these dockets include:
- claim construction and infringement analysis,
- novelty/obviousness and enablement challenges,
- written description and indefiniteness,
- non-infringement based on product differences,
- appeal standards for summary judgment or claim construction,
- entitlement to remedies.
No specific issue framing is available in the input.
When does exclusivity expire, and how does that drive litigation leverage in 23-1953?
Answer: Exclusivity timelines (patent expiration dates, regulatory exclusivities such as 5/7/3-year bars or pediatric exclusivity, and any FDA approval-date anchors) are not provided in the input.
Does the appeal turn on patent expiry versus final judgment?
Answer: Not provided. Without the district outcome and patent list, the timing mechanics cannot be stated.
Is there a Paragraph IV challenge or ANDA-related entry risk in 23-1953?
Answer: The input does not specify whether Accord’s FDA submission was an ANDA with a Paragraph IV certification, or whether the litigation is otherwise tied to an FDA pathway that uses Orange Book patent certifications.
What certifications were made, and which patents were “not included” or “carved out”?
Answer: Not provided.
What is the Orange Book status of the Purdue-listed patents in 23-1953?
Answer: Orange Book listing details are not provided in the input, including:
- the specific Orange Book publication number,
- dosage form and strength matched to the asserted patents,
- patent numbers and listed expiration,
- periods of exclusivity tied to the listed NDA/BLA.
How strong is Purdue’s patent estate against Accord based on the appeal posture?
Answer: A strength assessment requires:
- which patents were asserted and sustained at the district court,
- whether any patents were found invalid and if so on what grounds,
- whether claim construction favored Purdue,
- whether the appellate court is reviewing claim construction de novo or under a clear error standard in the posture relevant to the issues raised.
Those specifics are not provided in the input.
What is the settlement or injunction status of Purdue v. Accord Healthcare?
Answer: The input does not state whether:
- any stipulated settlement was reached,
- there is a final injunction,
- any stay applies pending appeal,
- entry has been enjoined or allowed.
How does 23-1953 compare with other Purdue opioid patent battles?
Answer: Comparative analysis requires specific details:
- the product and patent families asserted in each case,
- whether the parties are the same generic challengers,
- whether outcomes were sustained or reversed on appeal.
Those details are not provided in the input.
What generic entry risks exist for Accord after 23-1953?
Answer: Entry risk depends on the final appellate outcome and whether any injunction remains in place. The input does not provide the appellate result, so launch risk cannot be quantified.
Key takeaways
- The docket number 23-1953 identifies an appellate stage of Purdue Pharma L.P. v. Accord Healthcare, Inc.
- The input does not contain the case’s factual and legal specifics needed to summarize holdings, identify asserted patents, or determine the injunction and entry implications.
- Without those specifics, no actionable timeline, patent-by-patent analysis, or risk rating for Accord’s launch can be provided.
FAQs
- What is the procedural posture of Purdue Pharma L.P. v. Accord Healthcare, Inc., 23-1953?
- Which Orange Book patents are asserted by Purdue in the Accord litigation?
- What claims or patent types (composition, method-of-use, formulation) are central to 23-1953?
- Does the appeal affect FDA approval status or only enforceability of specific patents?
- What remedies were sought and what relief was granted or denied at the district court level?
References
- Purdue Pharma L.P. v. Accord Healthcare, Inc., No. 23-1953 (U.S. Court of Appeals docket entry).
